Synapse - Jan Bewersdorf

Results (103)

Contemporary approach to the diagnosis and classification of myelodysplastic neoplasms/syndromes—Recommendations from the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])

Review

Aakash, F.; Gisriel, S. D.; Zeidan, A. M.; Bennett, J. M.; Bejar, R.; Bewersdorf, J. P.; Borate, U. M.; Boultwood, J.; Brunner, A. M.; Buckstein, R.; more...
Modern Pathology (2024)

Fulltext@MSK | Save

TP53 Y220C mutations in patients with myeloid malignancies

Research Letter

Gener-Ricos, G.; Bewersdorf, J. P.; Loghavi, S.; Bataller, A.; Goldberg, A. D.; Sasaki, K.; Famulare, C.; Takahashi, K.; Issa, G. C.; Borthakur, G.; more...
Leukemia and Lymphoma (2024)

Fulltext@MSK | Save

Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML

Journal Article

Bewersdorf, J. P.; Shimony, S.; Shallis, R. M.; Liu, Y.; Berton, G.; Schaefer, E. J.; Zeidan, A. M.; Goldberg, A. D.; Stein, E. M.; Marcucci, G.; more...
Blood Advances (2024)

Fulltext@MSK | Save

Clinical and genomic-based decision support system to define the optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndromes

Journal Article

Tentori, C. A.; Gregorio, C.; Robin, M.; Gagelmann, N.; Gurnari, C.; Ball, S.; Berrocal, J. C. C.; Lanino, L.; D'Amico, S.; Spreafico, M.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia

Journal Article

Bewersdorf, J. P.; Patel, K. K.; Shallis, R. M.; Podoltsev, N. A.; Kewan, T.; Stempel, J.; Mendez, L.; Stahl, M.; Stein, E. M.; Huntington, S. F.; more...
Leukemia and Lymphoma (2024)

Fulltext@MSK | Save

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study

Correspondence

Bewersdorf, J. P.; Shimony, S.; Shallis, R. M.; Liu, Y.; Berton, G.; Schaefer, E. J.; Zeidan, A. M.; Goldberg, A.; Stein, E.; Marcucci, G.; more...
American Journal of Hematology (2024)

Fulltext@MSK | Save

Treatment of myelodysplastic syndromes for older patients: Current state of science, challenges, and opportunities

Review

Kewan, T.; Stahl, M.; Bewersdorf, J. P.; Zeidan, A. M.
Current Hematologic Malignancy Reports (2024)

Fulltext@MSK | Save

Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine

Journal Article

Zeidan, A. M.; Bewersdorf, J. P.; Hasle, V.; Shallis, R. M.; Thompson, E.; de Menezes, D. L.; Rose, S.; Boss, I.; Halene, S.; Haferlach, T.; more...
Therapeutic Advances in Hematology (2024)

Fulltext@MSK | Save

Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)